

## Edarbyclor - (40 mg/12.5 mg and 40 mg/25 mg ; Tablet)

<b>Generic Name</b>	Azilsartan Medoxomil and Chlorthalidone	<b>Innovator</b>	Azurity (Arbor)
<b>Dosage</b>	40 mg/12.5 mg and 40 mg/25 mg ; Tablet	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	None
<b>Indication</b>	Edarbyclor is an angiotensin II receptor blocker (ARB) and a thiazidelike diuretic combination product indicated for the treatment of hypertension, to lower blood pressure: • In patients not adequately controlled with monotherapy • As initial therapy in patients likely to need multiple drugs to help achieve blood pressure goals		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.